Deals of the Week: Stada/Grunenthal, Stada/Spirig, Shire/Sangamo
While 2012 promises to be a lucrative for generic drug companies, they now face their own reverse patent cliff. Some, therefore, are looking to diversify into branded products.
You may also be interested in...
Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.
Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.
Shire expects only a gradual pick up of competitive pressure from Genzyme's resumption of Fabrazyme manufacturing, with the double-digit growth of revenues in 2011 set to be replicated in 2012.